Overall Survival with Amivantamab-Lazertinib in <i>EGFR</i>-Mutated Advanced NSCLC.

Yang JC, Lu S, Hayashi H, Felip E, Spira AI, Girard N, Kim YJ, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Passaro A, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Kim SW, Gadgeel SM, Owen S, Xie J, Sun T, Mehta J, Venkatasubramanian R, Ennis M, Fennema E, Daksh M, Roshak A, Man J, Knoblauch RE, Bauml JM, Baig M, Shah S, Sethi S, Cho BC, MARIPOSA Investigators.

Open source

DOI
10.1056/nejmoa2503001
Published
2025-09-07
Container
N Engl J Med
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2503001,
  title = {Overall Survival with Amivantamab-Lazertinib in \<i\>EGFR\</i\>-Mutated Advanced NSCLC.},
  author = {Yang JC and  Lu S and  Hayashi H and  Felip E and  Spira AI and  Girard N and  Kim YJ and  Lee SH and  Ostapenko Y and  Danchaivijitr P and  Liu B and  Alip A and  Korbenfeld E and  Mourão Dias J and  Besse B and  Passaro A and  Lee KH and  Xiong H and  How SH and  Cheng Y and  Chang GC and  Yoshioka H and  Thomas M and  Nguyen D and  Ou SI and  Mukhedkar S and  Prabhash K and  D'Arcangelo M and  Alatorre-Alexander J and  Vázquez Limón JC and  Alves S and  Stroyakovskiy D and  Peregudova M and  Şendur MAN and  Yazici O and  Califano R and  Gutiérrez Calderón V and  de Marinis F and  Kim SW and  Gadgeel SM and  Owen S and  Xie J and  Sun T and  Mehta J and  Venkatasubramanian R and  Ennis M and  Fennema E and  Daksh M and  Roshak A and  Man J and  Knoblauch RE and  Bauml JM and  Baig M and  Shah S and  Sethi S and  Cho BC and  MARIPOSA Investigators.},
  year = {2025},
  journal = {N Engl J Med},
  doi = {10.1056/nejmoa2503001},
  url = {https://doi.org/10.1056/nejmoa2503001}
}

RIS

TY  - JOUR
TI  - Overall Survival with Amivantamab-Lazertinib in <i>EGFR</i>-Mutated Advanced NSCLC.
AU  - Yang JC
AU  -  Lu S
AU  -  Hayashi H
AU  -  Felip E
AU  -  Spira AI
AU  -  Girard N
AU  -  Kim YJ
AU  -  Lee SH
AU  -  Ostapenko Y
AU  -  Danchaivijitr P
AU  -  Liu B
AU  -  Alip A
AU  -  Korbenfeld E
AU  -  Mourão Dias J
AU  -  Besse B
AU  -  Passaro A
AU  -  Lee KH
AU  -  Xiong H
AU  -  How SH
AU  -  Cheng Y
AU  -  Chang GC
AU  -  Yoshioka H
AU  -  Thomas M
AU  -  Nguyen D
AU  -  Ou SI
AU  -  Mukhedkar S
AU  -  Prabhash K
AU  -  D'Arcangelo M
AU  -  Alatorre-Alexander J
AU  -  Vázquez Limón JC
AU  -  Alves S
AU  -  Stroyakovskiy D
AU  -  Peregudova M
AU  -  Şendur MAN
AU  -  Yazici O
AU  -  Califano R
AU  -  Gutiérrez Calderón V
AU  -  de Marinis F
AU  -  Kim SW
AU  -  Gadgeel SM
AU  -  Owen S
AU  -  Xie J
AU  -  Sun T
AU  -  Mehta J
AU  -  Venkatasubramanian R
AU  -  Ennis M
AU  -  Fennema E
AU  -  Daksh M
AU  -  Roshak A
AU  -  Man J
AU  -  Knoblauch RE
AU  -  Bauml JM
AU  -  Baig M
AU  -  Shah S
AU  -  Sethi S
AU  -  Cho BC
AU  -  MARIPOSA Investigators.
PY  - 2025
JO  - N Engl J Med
DO  - 10.1056/nejmoa2503001
UR  - https://doi.org/10.1056/nejmoa2503001
ER  -

APA

JC, Y., S, L., H, H., E, F., AI, S., N, G., YJ, K., SH, L., Y, O., P, D., B, L., A, A., E, K., J, M. D., B, B., A, P., KH, L., H, X., SH, H., Y, C., GC, C., H, Y., M, T., D, N., SI, O., S, M., K, P., M, D., J, A., JC, V. L., S, A., D, S., M, P., MAN, Ş., O, Y., R, C., V, G. C., F, D. M., SW, K., SM, G., S, O., J, X., T, S., J, M., R, V., M, E., E, F., M, D., A, R., J, M., RE, K., JM, B., M, B., S, S., S, S., BC, C., & Investigators., M. (2025). Overall Survival with Amivantamab-Lazertinib in <i>EGFR</i>-Mutated Advanced NSCLC.. N Engl J Med. https://doi.org/10.1056/nejmoa2503001

Source records